Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela sold 4,358 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total value of $17,998.54. Following the completion of the transaction, the chief executive officer owned 768,931 shares in the company, valued at $3,175,685.03. The trade was a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

TriSalus Life Sciences Stock Up 1.8%

Shares of TLSI opened at $3.93 on Monday. TriSalus Life Sciences, Inc. has a 52-week low of $3.42 and a 52-week high of $7.95. The stock has a market cap of $240.95 million, a PE ratio of -2.15 and a beta of 0.42. The firm’s fifty day moving average is $4.91 and its two-hundred day moving average is $5.29.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. As a group, research analysts anticipate that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Canaccord Genuity Group cut their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. Finally, Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently modified their holdings of TLSI. Invesco Ltd. acquired a new stake in shares of TriSalus Life Sciences during the 4th quarter worth about $72,000. Man Group plc acquired a new position in TriSalus Life Sciences in the fourth quarter valued at about $102,000. Abel Hall LLC purchased a new position in TriSalus Life Sciences during the fourth quarter worth about $73,000. Kotler Kevin purchased a new position in TriSalus Life Sciences during the fourth quarter worth about $1,013,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at about $104,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
• Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
• Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
• Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
• Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.